INTRODUCTION {#sec0005}
============

Alzheimer's disease (AD), the most common type of dementia in elderly individuals, slowly and progressively diminishes cognitive function, impairs activities of daily living, and imposes physical, mental, and economic burdens on patients and their caregivers \[[@ref001]\]. The pathophysiological process in AD begins years before the onset of cognitive symptoms \[[@ref002]\]. Patients in the predementia phase of AD, called mild cognitive impairment (MCI) due to AD, are converted to AD dementia at a rate of 16.1% over 1 year \[[@ref003]\] and 36.3% over 2 years \[[@ref004]\] according to studies by the Alzheimer's Disease Neuroimaging Initiative (ADNI). According to a systematic review by Ward et al. \[[@ref005]\], conversion rates from MCI or amnestic MCI to AD dementia over 5 or more years were greater than 33% in most clinic-based and community-based studies \[[@ref006]\]. Although disease-modifying treatments for AD dementia or MCI due to AD--- therapeutic agents that can inhibit progression of the disease by acting on the pathophysiological process and delaying neurodegeneration or neuronal loss--- remain to be approved, vigorous development of novel disease-modifying treatments and their clinical trials are ongoing.

Clinical trials of AD-modifying treatments require longer periods of time and larger sample sizes than those of symptomatic drugs (e.g., acetylcholinesterase inhibitors or N-methyl-D-aspartate receptor antagonists) \[[@ref010]\]. To reduce the duration of clinical trials and sample sizes required, it is essential to establish a valid biomarker suitable for tracking disease progression that has higher precision and lower variance than the current gold-standard outcome measures based on neuropsychological examinations such as the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) \[[@ref011]\] or Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) \[[@ref012]\]. Furthermore, the biomarker should have high sensitivity for disease progression, high biological plausibility, and a strong relationship with the clinical features of AD \[[@ref014]\].

Quantitative brain atrophy measurement over months or years calculated from serial magnetic resonance imaging (MRI) scans is one of the most promising progression biomarkers being explored. This biomarker could enable physicians to track disease progression and the therapeutic effects of disease-modifying treatments. Such approaches are a potential alternative to conventional neuropsychological measures and have shown greater statistical power to detect longitudinal changes than neuropsychological measures in ADNI studies \[[@ref015]\]. Such a surrogate biomarker may play a key role in clinical trials and accelerate the development of novel drugs, as noted by Cummings et al. \[[@ref022]\].

Among patients with AD and MCI, several studies showed greater atrophic rates of change in the hippocampus and temporal lobe of carriers of theapolipoprotein E gene allele *ɛ*4 (*ApoE* *ɛ*4)--- the strongest risk factor for AD \[[@ref023]\]--- than in those of *ApoE* *ɛ*4 non-carriers \[[@ref024]\]. These two research groups also found that sample sizes estimated from *ApoE* *ɛ*4 carriers with MCI are smaller than those estimated from *ApoE* *ɛ*4 non-carriers with MCI. Thus, *ApoE* status could contribute to AD drug trial enrichment.

Although many reports have been published by the ADNI estimating sample sizes using cerebral atrophic rates or amounts derived from serial structural MRI \[[@ref015]\], no reports are available on power calculations or estimates of sample size in Japan. While about 90% of the ADNI participants were white \[[@ref003]\], all of the Japanese ADNI (J-ADNI) participants were Asian (Japanese). Thus, it is crucial to estimate how large a sample size would be needed for future clinical trials in Japan using atrophy measures from serial MRI as a surrogate biomarker. Accordingly, in the present study, we used an automated segmentation technique for the whole brain and hippocampus and the k-means normalized boundary shift integral (KN-BSI) to calculate the atrophy rates and estimate the sample sizes from serial MRI scans in the J-ADNI study for boosting the development of AD-modifying treatments. The automated segmentation of the hippocampus conformed to the standard segmentation protocol--- harmonized protocol--- that was recently developed by the ADNI and European Alzheimer's Disease Consortium working group \[[@ref026]\]. The BSI was adopted in the present study because it has been used in several clinical trials for AD therapies, including those of the first anti--β-amyloid vaccine (AN1792) \[[@ref027]\], acetylcholinesterase inhibitors \[[@ref028]\], and an N-methyl-D-aspartate receptor antagonist \[[@ref031]\]. In addition, we examined whether *ApoE* status contributed to drug trial enrichment in the J-ADNI dataset.

METHODS {#sec0010}
=======

Participants {#sec0015}
------------

Participants were recruited in the J-ADNI study. The J-ADNI was a multicenter study assessing neuroimaging in diagnosis and longitudinal monitoring that was started in 2008 in Japan by the New Energy and Industrial Technology Development Organization (NEDO) and the Ministry of Health, Labour and Welfare (MHLW). All of the participants were recruited at 38 Japanese clinical sites. They were followed up for 2--3 years using 1.5-T MRI, positron emission tomography (PET), biological fluid analysis, and neuropsychological batteries. All of the protocols were designed to be as compatible as possible to those of the ADNI. For additional details about the J-ADNI, see the previous article by the J-ADNI \[[@ref032]\].

Participants were 60 to 84 years of age, generally healthy, spoke Japanese, lived at home, and had a study partner. Details of the J-ADNI inclusion and exclusion criteria can be found at <https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001668>. Briefly, the inclusion criteria for cognitively normal (CN) participants included the following: a score of 24--30 on the Mini-Mental State Examination (MMSE) \[[@ref033]\], Japanese version; a global score of 0 on the CDR, Japanese version; and an education-adjusted score above the cutoff level on the Wechsler Memory Scale-Revised (WMS-R) Logical Memory II \[[@ref034]\], Japanese version (education for 0--9 years was ≥3, for 10--15 years was ≥5, and for \>15 years was ≥9). The inclusion criteria for the MCI subjects were a score of 24--30 on the MMSE, memory disturbance identified by the study partner with or without the subjective complaint of the participant, a score of 0.5 on the CDR, and an education-adjusted score below the cutoff level on the WMS-R Logical Memory II (education for 0--9 years was ≤2, for 10--15 years was ≤4, and for \>15 years was ≤8). The inclusion criteria for AD subjects was a score of 20--26 on the MMSE score, a score of 0.5 or 1 on the CDR, and an education-adjusted score below the cutoff level on the WMS-R Logical Memory II (same as for MCI). AD subjects also had to meet the criteria of the NINCDS-ADRDA (the National Institute of Neurological and Communicative Diseases and Stroke and the Alzheimer's Disease and Related Disorders Association) \[[@ref035]\] for probable AD. Exclusion criteria included brain lesions on screening or baseline MRI, neurological and psychiatric disorders other than AD, addiction to alcohol or other drugs, and use of psychoactive drugs or warfarin.

The institutional review boards at all participating sites approved the data collection procedures and written informed consent was obtained from all participants. If participants were not capable of agreeing, their study partner signed the informed consent form in substitution.

A total of 750 participants were first recruited at the 38 clinical sites in Japan. Those who provided written informed consent and passed screening based on the above inclusion/exclusion criteria were enrolled in the J-ADNI study. Finally, 537 participants were enrolled. The 537 participants underwent brain MRI at baseline. Follow-up MRI was performed at 6, 12, and 24 months for all participants and at 36 months only for MCI and CN participants. MCI participants additionally underwent MRI at 18 months. Clinical and cognitive assessments were also performed for all participants at the time of the baseline and follow-up scans. These assessments included MMSE, ADAS-Cog, and CDR-SB. Data were used for analysis from 149 AD, 234 MCI, and 154 CN participants. Clinical and demographic data are shown in [Table 1](#jad-56-jad160621-t001){ref-type="table"}. The participants' IDs and visits used in the present study are listed in [Supplementary Material A](#S1){ref-type="supplementary-material"}.

Data for the automated segmentation atlas set {#sec0020}
---------------------------------------------

Data used in the preparation of the atlas set for the automated segmentation described in [Supplementary Material B](#S2){ref-type="supplementary-material"} were obtained from the ADNI database (<http://adni.loni.usc.edu>). The ADNI was launched in 2003 as a public--private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial MRI, PET, other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of MCI and early AD. For up-to-date information, see <http://www.adni-info.org>.

MRI acquisition and image correction {#sec0025}
------------------------------------

Structural MR images were acquired on 1.5-T MRI scanners from three vendors (GE Healthcare, Milwaukee, WI; Siemens Medical Solutions, Erlangen, Germany; and Philips Medical Systems, Best, The Netherlands) using a three-dimensional sagittal magnetization-prepared rapid gradient-echo imaging (MPRAGE) sequence. Typical acquisition parameters were an inversion time of 1000 ms, repetition time of 2400 ms, minimum echo time, flip angle of 8°, field of view of 240×240 mm^2^, and in-plane resolution of 192×192 (1.25×1.25 mm^2^) or 256×256 (0.94×0.94 mm^2^) with slice thickness of 1.2 mm.

In this study, 3D MR images were acquired at 38 sites using scanners from the three different vendors. We performed the following three-step approach to minimize variations among scanners. First, we used a consistent MRI pulse sequence for MPRAGE over time. The MPRAGE sequence was used for all scanners to enhance gray/white matter contrast for superior gray/white matter segmentation. The parameters of the MPRAGE were chosen to be as close as possible to those of the MRI sequence of the US-ADNI \[[@ref036]\]. For GE scanners, we installed a customized MPRAGE sequence with the permission of the University of Virginia.

Second, we checked whether any images suffered serious degradation due to motion artifacts, aliasing artifacts inside the skull, low signal-to-noise ratio, signal loss, or metal artifacts. Seriously degraded images were excluded to alleviate the influences of degradation on the results of the longitudinal and cross-sectional analyses.

Third, original MR images were pre-processed with the N3 intensity inhomogeneity correction \[[@ref037]\] for all scanners and the B1 correction for scanners with a phased array receive coil to reduce intensity inhomogeneity due to non-uniform sensitivity of the receive coil \[[@ref038]\]. Subsequently, phantom-based distortion correction \[[@ref039]\] was performed to correct geometric distortion caused by the gradient non-linearity and static magnetic field inhomogeneity of each scanner.

Image processing {#sec0030}
----------------

Our fully automated measurement procedure for the assessment of whole brain and hippocampalatrophy in serial MRI scans consists of two components: (1) automated segmentation of the whole brain and hippocampus using the multi-atlas image segmentation approach \[[@ref040]\] and the corrective learning technique \[[@ref041]\]; and (2) KN-BSI using multi-time-point symmetric affine registration with symmetric differential bias correction \[[@ref019]\]. For full details and assessments of this quantification procedure, see [Supplementary Material B](#S2){ref-type="supplementary-material"}. Moreover, for head-to-head comparison with this procedure using the same dataset of the J-ADNI, one of the current state-of-the-art image analysis methods--- FreeSurfer version 5.3 cross-sectional and longitudinal stream \[[@ref047]\]--- was used to estimate the atrophic changes of specific regions, including the hippocampal volume, lateral ventricle volume, and entorhinal cortical thickness, from serial MRI scans. The lateral ventricle consisted of the left and right lateral ventricles and inferior lateralventricles.

Recently, FreeSurfer has been shown to have similar reproducibility for atrophic measurements as manual hippocampal segmentation \[[@ref050]\]. In the present study, no manual editing or exclusion due to processing failure was done at any stage of our procedure using KN-BSI and FreeSurfer. Note that FreeSurfer did not complete the cross-sectional stream for one participant (ID = JADNI0563, at 18 months) and the longitudinal stream for two participants (ID = JADNI0048, at 24 months and ID = JADNI0602, at 6 months).

ApoE genotyping {#sec0035}
---------------

Of the 537 participants, 534 agreed to blood sampling for *ApoE* genotyping. Genomic DNA was extracted from peripheral blood using a QIAamp DNA Blood Maxi Kit (Qiagen, Dusseldorf, Germany) and was examined fluorometrically using a PicoGreen dsDNA quantification kit (Molecular Probes, Eugene, OR). *ApoE* genotyping of all samples was determined by single nucleotide polymorphism (SNP) typing and was confirmed by DNA sequencing. SNP genotyping of individual samples was done using an ABI PRISM 7900HT instrument using TaqMan technology. TaqMan SNP Genotyping Assays were purchased from Applied Biosystems (Foster City, CA). Sequencing was carried out by direct cycle sequencing with an ABI 3100 sequencer and a BigDye Terminator v3.1 kit (Applied Biosystems) using the following primers: C19APOE001-F (sense 5^′^-GCCTACAAAT CGGAACTGGA-3^′^) and C19APOE001-R (antisense 5^′^-ACCTGCTCCT TCACCTCGT-3^′^).

*ApoE* *ɛ*2 may protect against AD development \[[@ref051]\]. In fact, when *ApoE* *ɛ*3/*ɛ*3 carriers have a reference odds ratio of 1.0, the odds ratio for AD development for *ApoE* *ɛ*2/*ɛ*4 carriers is 2.4, with its 95% confidence interval including the value 1.0 (0.4 to 15.4); in contrast, the odds ratios (95% confidence interval) for AD development for *ApoE* *ɛ*3/*ɛ*4 carriers and *ApoE* *ɛ*4/*ɛ*4 carriers are 5.6 (3.9 to 8.0) and 33.1 (13.6 to 80.5) in Japanese subjects, respectively \[[@ref052]\]. However, in the present study, the frequency of *ApoE* *ɛ*2/*ɛ*4 carriers was very small: 1.3% both for AD and CN participants while no MCI individuals were carriers ([Table 1](#jad-56-jad160621-t001){ref-type="table"}). Therefore, we regarded *ApoE* *ɛ*2/*ɛ*4 carriers as *ApoE* *ɛ*4 carriers.

Statistical analyses {#sec0040}
--------------------

We used sample size estimation to evaluate the neuropsychological examination scores (CDR-SB, ADAS-Cog (the modified 13-item version) \[[@ref013]\], and MMSE) and the measures from serial MRI using KN-BSI. Statistical analyses were separately performed for the MRI brain atrophy measures and cognitive measures. At each visit, if an MPRAGE scan was judged not to be suitable for image analysis at quality control assessments (e.g., due to gross motion artifacts) or the image processing resulted in failure, only cognitive measures at the same visit of the same participant were included in the statistical analysis ([Fig. 1](#jad-56-jad160621-g001){ref-type="fig"}). Please note that cognitive measures were obtained at every visit for all participants. Adopting a previous method \[[@ref025]\], we considered two-arm and equal allocation trials for a hypotheticalAD-modifying treatment versus placebo with the scores and above measures as the longitudinal outcomes and with two durations, 1 year and 2 years. In this setting, we calculated sample sizes to detect a 25% reduction in the mean rate of change (annual change) in the outcomes during the trial period with 80% power and a two-sided significance level of 5% with and without comparison to normal aging.

The power analysis is based on a linear mixed-effects model with random intercepts and slopes. Let *Y*~*ij*~ be the longitudinal outcome for the *i*-th subject and *j*-th measurement time and *t*~*j*~ be the *j*-th measurement time in year, then our model is considered as follows: $$Y_{\mathit{ij}} = \beta_{0} + \beta_{1}t_{j} + \alpha_{0} + \alpha_{1}t_{j} + ɛ_{\mathit{ij}}$$

where β~0~ and β~1~ are a fixed intercept and slope, respectively, α~0~ and α~1~ are a random intercept and slope, respectively, assuming bivariate normal distribution, and *ɛ*~*ij*~ is the error term with a normal distribution and mean equal and variance $\sigma_{ɛ}^{2}$. In the power analysis, among the parameters in the bivariate normal distribution for α~0~ and α~1~, we used only the variance of the random slope α~1~, which was denoted as $\sigma_{s}^{2}$. This model was applied to data for one-diseased subjects (e.g., AD) and estimated the annual change denoted by ${\widehat{\beta}}_{1}$ and its variation represented by estimators ${\widehat{\sigma}}_{s}^{2}$ and ${\widehat{\sigma}}_{ɛ}^{2}$. These estimators were considered as for the placebo group and the 25% reduction in the annual change in the active group was determined by $\Delta = 0.25{\widehat{\beta}}_{1}$ and the same variation between the active and placebo groups was assumed. Compared with normal aging, $\Delta = 0.25\left( {{\widehat{\beta}}_{1} - {\widehat{\beta}}_{N}} \right)$, where ${\widehat{\beta}}_{N}$ is the estimated slope from normal subjects. Namely, the treatment effect size of interest *Δ* was set to 25% of the mean rate of change seen in the AD or MCI participants when normal aging was not controlled, whereas the treatment effect size was set to 25% of the mean rate of change seen in the AD or MCI participants minus that seen in the CN participants. Thus, we used the following formula for the sample size with the significance level α and the power 1 - β provided by \[[@ref053]\]:

$$\begin{array}{rcl}
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 & & {\quad = \frac{2\left( {\sigma_{s}^{2} + \sigma_{ɛ}^{2}/\Sigma\left( {t_{j} - \overline{t}} \right)^{2}} \right)\left( {z_{1 - \alpha/2} + z_{1 - \beta}} \right)^{2}}{\Delta^{2}}} \\
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\end{array}$$ where *z*~*a*~ denotes the (1 - *a*)× 100 % percentile of a standard normal distribution and $\overline{t}$ denotes the mean measurement time. In this formula, $\sigma_{s}^{2}$ and $\sigma_{ɛ}^{2}/\Sigma\left( {t_{j} - \overline{t}} \right)^{2}$ respectively represent the between- and the within-subject variance for the slope.

For the 1-year trial, data at baseline, 6 months, and 12 months were used. For the 2-year trial, data at baseline, 6 months, 12 months, and 24 months were analyzed. In addition, data at 18 months were included in the analyses of the MCI participants. Furthermore, sample sizes were separately estimated for *ApoE* *ɛ*4 carriers and non-carriers.

In addition, to perform head-to-head comparisons of sample sizes between cognitive and MRI-derived measures, the confidence intervals of the paired differences in the sample sizes from the two measures were calculated using a bootstrap sampling procedure. Samples were drawn randomly from the original samples with replacement and the number of samples was the same as the original. The sampling was repeated 10000 times, that is, 10000 bootstrap samples were obtained. When the 95% confidence interval (from the 2.5th to the 97.5th percentiles) did not include the null value of zero, the difference was assessed to be statistically significant at the 5% level.

All statistical analyses were performed using R version 3.2.1 \[[@ref055]\] and the "longpower" package \[[@ref056]\].

RESULTS {#sec0045}
=======

Sample size comparison between neuropsychological measuresand MRI-derived measures {#sec0050}
----------------------------------------------------------------------------------

The rates of change of the hippocampal volume using KN-BSI consistently provided a smaller sample size than the neuropsychological examination scores in AD and MCI with and without controlling for normal aging, assuming a 12-month trial (see [Tables 2](#jad-56-jad160621-t002){ref-type="table"} and [3](#jad-56-jad160621-t003){ref-type="table"}) and a 24-month trial (see [Supplementary Table C1 and C2 in Supplementary Material C](#S3){ref-type="supplementary-material"}). Although the rates of change estimated from the whole brain volume provided a smaller sample size than those from CDR-SB, ADAS-Cog, and MMSE in AD and MCI patients without controlling for normal aging, they provided comparable or larger sample sizes than those from the cognitive measures CDR-SB and ADAS-Cog after controlling for normal aging. The sample sizes after controlling for normal aging in a 12-month trial were 2.5 to 3.5 times larger for the atrophic changes of the whole brain and about 1.5 times larger for the atrophic changes of the hippocampus than those obtained without controlling for normal aging in AD and MCI patients. KN-BSI, FreeSurfer, and cognitive measures are compared in [Tables 5](#jad-56-jad160621-t005){ref-type="table"} and [6](#jad-56-jad160621-t006){ref-type="table"}. As shown in [Table 5](#jad-56-jad160621-t005){ref-type="table"}, the best measure among MRI-derived measures using KN-BSI and FreeSurfer was the rate of change in the hippocampus using KN-BSI, followed by the rates of change in the cortical thickness in the entorhinal cortex and hippocampus by the FreeSurfer longitudinal stream and the whole brain using KN-BSI after controlling for normal aging. [Table 6](#jad-56-jad160621-t006){ref-type="table"} shows the sample size comparison of KN-BSI, FreeSurfer, and cognitive measures using a bootstrap sampling procedure. KN-BSI hippocampus offered significantly smaller sample sizes than almost all of the FreeSurfer-derived and cognitive measures in AD and MCI patients with and without controlling for normal aging.

Overall, the hippocampal atrophy rates obtained using KN-BSI provided a smaller sample size than the other MRI and cognitive measures in a 12-month trial after controlling for normal aging in AD and MCI patients with statistical significance based on the bootstrap sampling procedure, except for the hippocampal atrophy rates obtained using the FreeSurfer longitudinal stream in AD.

Effects of ApoE *ɛ*4 status on sample sizes and atrophic rates of change {#sec0055}
------------------------------------------------------------------------

[Table 4](#jad-56-jad160621-t004){ref-type="table"} presents the mean rates of change of the whole brain volume and hippocampal volume with 95% confidence intervals estimated from baseline, 6-month, and 12-month scans using the linear mixed-effects model in *ApoE* *ɛ*4 carriers and non-carriers with AD and MCI. The mean rates of change of the hippocampus of *ApoE* *ɛ*4 carriers were higher than those of *ApoE* *ɛ*4 non-carriers in the AD and MCI groups (*p* \< 0.05), whereas the whole brain of *ApoE* *ɛ*4 carriers offered a non-significant trend toward a higher mean rate of change than that of *ApoE* *ɛ*4 non-carriers with AD (*p* = 0.13) or MCI (*p* = 0.13). The sample sizes estimated from the rates of change of the whole brain volume and hippocampal volume of *ApoE* *ɛ*4 carriers were smaller than those of *ApoE* *ɛ*4 non-carriers, with the hippocampal rate of change in *ApoE* *ɛ*4 carriers requiring 116 patients with AD and 145 patients with MCI after controlling for normal aging in a 12-month trial. In a 12-month clinical trial of MCI, sample sizes estimated from *ApoE* *ɛ*4 carriers after controlling for normal aging were 28.9% smaller in the KN-BSI whole brain (from 785 to 558 subjects/arm) and 47.7% smaller in the KN-BSI hippocampus (from 277 to 145 subjects/arm) than those estimated without information on *ApoE* status. In a 12-month trial of AD, sample sizes estimated from *ApoE* *ɛ*4 carriers while controlling for normal aging were 36.3% smaller in the KN-BSI whole brain (from 386 to 246 subjects/arm) and 34.1% smaller in the KN-BSI hippocampus (from 176 to 116 subjects/arm) than those estimated without information on *ApoE* status.

DISCUSSION {#sec0060}
==========

Our results indicate that atrophic changes in the hippocampus using KN-BSI on serial MRI offers a significantly smaller sample size for detecting a reduced disease progression by a hypothetical AD- and MCI-modifying treatment than that estimated from neuropsychological examination scores in ethnic Japanese. In addition, the results show that assessment of *ApoE* *ɛ*4 status is a promising drug trial enrichment strategy to reduce sample size. The image analysis procedure used automated segmentation of the whole brain and hippocampus, symmetric affine registration, and KN-BSI and was evaluated in terms of symmetry, transitivity, comparison with the state-of-the-art FreeSurfer tool, and reproducibility using short-interval scan pairs, based on cautionary notes proposed by Fox et al. \[[@ref057]\], as well as the accuracy of the automated segmentation (see [Tables 5](#jad-56-jad160621-t005){ref-type="table"} and [6](#jad-56-jad160621-t006){ref-type="table"} and [Supplementary Material B](#S2){ref-type="supplementary-material"}).

In a 12-month trial for AD, the KN-BSI hippocampus offered 40.8% and 15.7% of the sample size of ADAS-Cog and 40.8% and 30.2% of that of CDR-SB with and without controlling for normal aging, respectively (see [Tables 2](#jad-56-jad160621-t002){ref-type="table"} and [3](#jad-56-jad160621-t003){ref-type="table"}). Holland et al. \[[@ref017]\] reported that the longitudinal hippocampal measure in AD patients provided 40.8% and 17.8% of the sample size of that of ADAS-Cog and 38.6% and 23.2% of that of CDR-SB with and without controlling for normal aging, respectively. In a 12-month trial for MCI, the KN-BSI hippocampus offered 26.7% and 13.7% of the sample size of ADAS-Cog and 42.0% and 30.1% of that of CDR-SB with and without controlling for normal aging, respectively (see [Tables 2](#jad-56-jad160621-t002){ref-type="table"} and [3](#jad-56-jad160621-t003){ref-type="table"}). In Holland et al. \[[@ref017]\], the authors reported that the longitudinal hippocampal measure in MCI patients provided 34.8% and 5.6% of the sample size of ADAS-Cog and 64.9% and 26.9% of that of CDR-SB with and without controlling for normal aging, respectively. Taken together, the sample sizes estimated from the KN-BSI hippocampus in AD patients with and without controlling for normal aging showed similar reductions in sample sizes as those reported by Holland et al. when they are compared with those estimated from the cognitive measures. However, the sample sizes estimated from the KN-BSI hippocampus in MCI patients while controlling for normal aging showed larger reductions in sample sizes than those in Holland et al. when compared with those estimated from the cognitive measures. One possible interpretation is that the proportion of MCI patients with more advanced disease status was larger in the present study than in the study by Holland et al. because the sample size reduction rates by the KN-BSI hippocampus in MCI patients compared with the cognitive measures were similar to those in AD patients.

In the present study, atrophic changes in structures in the medial temporal lobe, including the KN-BSI hippocampus and FreeSurfer longitudinal stream entorhinal cortex, offered smaller sample sizes than those estimated from other brain regions in AD and MCI patients (see [Table 5](#jad-56-jad160621-t005){ref-type="table"}). These findings support the view that the medial temporal lobe exhibits the first atrophic changes during the progression of AD \[[@ref058]\]. In contrast, sample sizes estimated by the rates of change in the KN-BSI whole brain and FreeSurfer longitudinal stream lateral ventricle were not as small as those in the KN-BSI hippocampus or FreeSurfer longitudinal stream entorhinal cortex after controlling for normal aging. Although sample sizes are relatively small without controlling for normal aging, the difference may be due to the larger sample sizes after controlling for normal aging because the regions did not show specific AD-related atrophy.

In comparison with the FreeSurfer longitudinal stream, the longitudinal volume change in the KN-BSI hippocampus offered a significantly smaller sample size after controlling for normal aging (see [Table 6](#jad-56-jad160621-t006){ref-type="table"}). Both the FreeSurfer longitudinal stream \[[@ref048]\] and the KN-BSI hippocampus compute brain volume changes of serial scans on a subject-specific template to minimize within-subject variability and maximize statistical power. However, the BSI "directly" computes volume changes by calculating voxel intensity differences between two serial scans at the boundary region of the whole brain or hippocampus, whereas the FreeSurfer longitudinal stream "indirectly" computes volume changes by separately calculating segmentations of the whole brain or hippocampus at each time point. The direct measurement has been reported to greater reduce within-group variability and increase statistical power than the indirect measurement \[[@ref020]\]. Moreover, the segmentation accuracies of our method using the multi-atlas image segmentation approach (see [Supplementary Table B1 in Supplementary Material B](#S2){ref-type="supplementary-material"}) in the Dice similarity coefficient are higher than those of FreeSurfer for the hippocampus, even though the validation data sets were different from each other. That is, the accuracies of our method versus those of FreeSurfer were 0.899±0.016 versus 0.82±0.015 for the left hippocampus and 0.894±0.016 versus 0.82±0.028 for the right hippocampus \[[@ref060]\]. These factors might have caused the significant differences in sample size estimates between our method and the FreeSurfer longitudinal stream.

*ApoE* *ɛ*4 carriers with AD and MCI provided smaller sample sizes than *ApoE* *ɛ*4 non-carriers and those of all of the participants in volume changes of the whole brain and hippocampus. These findings concur with the reports by Hua et al. and McEvoy et al. \[[@ref024]\]. In light of these results--- that *ApoE* status enabled reductions in sample sizes in the atrophy measures--- *ApoE* status could enrich future clinical trials of AD-modifying treatments. However, a trial enrichment strategy using *ApoE* status would require caution because a recent study has reported that *ApoE* *ɛ*4 carriers have a higher risk of amyloid-related imaging abnormalities than *ApoE* *ɛ*4 non-carriers in clinical trials of immunotherapy for reducing cerebral amyloid burden using bapineuzumab \[[@ref061]\]. For *ApoE* *ɛ*4 non-carriers, on the other hand, other clinical enrichment strategies based on a machine learning method that handles data from imaging biomarkers such as those of MRI and/or PET could enrich clinical trials by enabling the selection of participants who will show future cognitive and neural decline \[[@ref062]\].

To date, brain atrophy measurement using serial MRI scans has not been qualified as a surrogate endpoint for AD-modifying trials. However, the recent US Food and Drug Administration (FDA) draft guidance on the development of drugs for early-stage AD \[[@ref063]\] stated that they "are open to considering the argument that a positive biomarker result (generally included as a secondary outcome measure in a trial) in combination with a positive finding on a primary clinical outcome measure may support a claim of disease modification in AD", given that there is "widespread evidence-based agreement in the research community that the chosen biomarker reflects a pathophysiologic entity that is fundamental to the underlying disease process". Although brain atrophy measurement does not reflect the molecular pathophysiologic processes of AD, it could serve as an approximate surrogate biomarker of the severity of neuronal loss, neuronal shrinkage, and synaptic loss \[[@ref064]\]. Because the present study was a longitudinal observation study without any preventive or curative interventions, we could not reveal the effect of a disease-modifying therapy on brain atrophy measurement. In past clinical trials of drugs for mild-to-moderate AD patients using brain atrophy measure as an imaging endpoint, an unexpected paradoxical treatment effect--- increased brain volume loss--- was found in some study arm patients \[[@ref027]\]. In future clinical trials, it will be necessary to examine the effects of disease-modifying treatments on brain atrophy measurement and whether the paradoxical effect is transitory by long-term follow-up using MRI \[[@ref065]\].

The present study has several strengths. First, it includes a large number of participants who were followed up for 2 or 3 years using identical protocols for neuropsychological examinations and image acquisitions over 38 clinical sites in Japan. Second, it has *ApoE* genotype information on almost all of the participants, which enables less biased examination of the trial enrichment strategy using *ApoE* status. Third, a linear mixed-effects model was used to perform power analyses because it can handle missing data in longitudinal studies. Fourth, automated segmentation using the multi-atlas fusion provides high accuracies for the whole brain and hippocampus (see [Supplementary Material B1 in Supplementary Material B](#S2){ref-type="supplementary-material"}). Fifth, the image analysis procedures for calculating the longitudinal volume change using automated segmentation and KN-BSI were assessed using the methods proposed by Fox et al. \[[@ref057]\], including symmetry, transitivity, linearity, reproducibility, and comparison with the known pathophysiology of AD, in addition to the head-to-head comparison with FreeSurfer (see [Tables 5](#jad-56-jad160621-t005){ref-type="table"} and [6](#jad-56-jad160621-t006){ref-type="table"} and [Supplementary Tables B2--B4 in Supplementary Material B](#S2){ref-type="supplementary-material"}).

Conversely, the present study has several limitations. First, the participants' diagnoses were not based on neuropathological confirmation. Therefore, some participants assigned to the AD and MCI groups may have had cognitive decline due to causes other than AD. Cerebrospinal fluid biomarkers and/or brain PET imaging of amyloid and tau could help to exclude participants with other causes of cognitive decline. Second, we did not take into account the attrition rate in the sample size estimation. In a clinical trial of an AD-modifying treatment, some participants would drop out of the trial due to a large time commitment, a lack of incentive to continue the trial, or health problems. Sample sizes estimated when accounting for attrition are larger than those estimated without accounting for attrition. In the present study, the sample sizes were estimated from data that included images that underwent failed automated image processing in order to amplify the sample sizes and somewhat reflect the effect of attrition \[[@ref066]\]. Third, we did not perform manual editing or exclusion due to processing failure at any stage of our procedure using KN-BSI and FreeSurfer. If treatment and placebo arms are not equally balanced across MR scanners, lower segmentation quality due to scanner-specific susceptibility artifacts would induce an artifactual difference of treatment effect between the arms.

In conclusion, this study demonstrates the potential of longitudinal atrophic changes of the hippocampus using automated segmentation andthe KN-BSI on serial MRI as a progression biomarker that could offer a significantly smaller sample size than cognitive measures in a clinical trial of an AD-modifying treatment in a Japanese population. Moreover, *ApoE* *ɛ*4 status offers promise as a drug trial enrichment strategy to reduce sample size. Because some participants who had cognitive decline due to causes other than AD may have been included in the present study, future studies with inclusion/exclusion criteria using amyloid PET, tau PET, and/or cerebrospinal fluid biomarkers would provide more plausible sample size estimation for a clinical trial of AD-modifying treatments.
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###### 

Demographics of the J-ADNI participants (*n* = 537)

  Group    *n*     Age, y       Sex, M/F     Baseline MMSE         *ApoE* status
  ------- ----- ------------ -------------- --------------- ----------------------------
  AD       149   73.7 ± 6.6   43.0% /57.0%    22.5 ± 1.8     3.4/1.3/36.9/40.9/16.8/0.7
  MCI      234   73.0 ± 5.9   49.6% /50.4%    26.4 ± 1.7     4.3/0.0/43.2/44.4/7.3/0.8
  CN       154   68.3 ± 5.8   48.1% /51.9%    29.1 ± 1.3     5.8/1.3/70.1/21.4/1.3/0.0

AD, Alzheimer's disease; *ApoE*, apolipoprotein E; F, female; CN, cognitively normal; M, male; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; NA, not available; SD, standard deviation.

###### 

Sample size estimates for the AD and MCI groups using a linear mixed-effects model for neuropsychological tests^\*^

  Outcome measure                           Annual change±SE         $\sigma_{s}^{2}$   $\sigma_{ɛ}^{2}$   N/arm not controlling for   N/arm controlling for
  ----------------------------------- ----------------------------- ------------------ ------------------ --------------------------- -----------------------
  *CDR-SB*                                                                                                                            
  CN                                    0.07±0.05 \[−0.03, 0.17\]                                                                     
  All AD subjects                       1.61±0.17 \[1.27, 1.95\]           3.36               0.38             398 \[272, 637\]          434 \[297, 694\]
  *ApoE* *ɛ*4 non-carriers with AD      1.83±0.26 \[1.30, 2.35\]           3.13               0.38             292 \[178, 564\]          315 \[192, 608\]
  *ApoE* *ɛ*4 carriers with AD          1.46±0.23 \[1.01, 1.92\]           3.51               0.38             504 \[295, 1048\]         554 \[324, 1153\]
  All MCI subjects                      1.02±0.10 \[0.81, 1.22\]           1.61               0.38             575 \[399, 897\]          660 \[458, 1030\]
  *ApoE* *ɛ*4 non-carriers with MCI     0.75±0.14 \[0.48, 1.02\]           1.46               0.25             880 \[477, 2130\]        1064 \[577, 2576\]
  *ApoE* *ɛ*4 carriers with MCI         1.26±0.15 \[0.96, 1.56\]           1.64               0.49             414 \[272, 707\]          463 \[304, 790\]
  *ADAS-Cog*                                                                                                                          
  CN                                   −1.00±0.28 \[−1.55, −0.44\]                                                                    
  All AD subjects                       2.99±0.46 \[2.09, 3.89\]          11.00               8.13             766 \[454, 1556\]         431 \[255, 876\]
  *ApoE* *ɛ*4 non-carriers with AD      2.70±0.73 \[1.25, 4.16\]           6.82              10.39             948 \[408, 4182\]         506 \[218, 2233\]
  *ApoE* *ɛ*4 carriers with AD          3.17±0.59 \[2.00, 4.35\]          13.94               6.61             678 \[365, 1672\]         393 \[211, 968\]
  All MCI subjects                      2.53±0.33 \[1.89, 3.18\]           7.53               8.03             922 \[586, 1658\]         475 \[302, 854\]
  *ApoE* *ɛ*4 non-carriers with MCI     1.90±0.45 \[1.00, 2.80\]           3.80               8.82            1491 \[692, 5261\]         642 \[298, 2264\]
  *ApoE* *ɛ*4 carriers with MCI         3.11±0.47 \[2.18, 4.04\]          10.34               7.32             648 \[386, 1304\]         372 \[222, 748\]
  *MMSE*                                                                                                                              
  CN                                    0.14±0.14 \[−0.14, 0.42\]                                                                     
  All AD subjects                      −1.39±0.27 \[−1.93, −0.85\]         3.49               3.10            1263 \[660, 3330\]        1039 \[542, 2738\]
  *ApoE* *ɛ*4 non-carriers with AD     −1.65±0.44 \[−2.53, −0.77\]         3.57               3.30             944 \[408, 4119\]         799 \[345, 3489\]
  *ApoE* *ɛ*4 carriers with AD         −1.20±0.35 \[−1.89, −0.51\]         3.43               2.98            1631 \[665, 8653\]        1303 \[532, 6915\]
  All MCI subjects                     −1.57±0.17 \[−1.91, −1.22\]         1.87               2.34             670 \[453, 1091\]         563 \[380, 916\]
  *ApoE* *ɛ*4 non-carriers with MCI    −0.88±0.24 \[−1.36, −0.40\]         1.45               2.34            1982 \[837, 9329\]        1468 \[620, 6913\]
  *ApoE* *ɛ*4 carriers with MCI        −2.19±0.23 \[−2.65, −1.73\]         1.72               2.27             327 \[224, 523\]          288 \[197, 461\]

^\*^The number of subjects per arm required to detect a 25% reduction in the mean rate of decline at the *p* \< 0.05 level with 80% power, assuming a 12-month trial with neuropsychological examinations every 6 months, is shown before and after controlling for normal aging. CDR-SB, Clinical Dementia Rating Scale Sum of Boxes score; ADAS-Cog, Alzheimer's Disease Assessment Scale-Cognitive Subscale score; SE, standard error of the mean; CI, confidence interval; AD, Alzheimer's disease; MCI, mild cognitive impairment; $\sigma_{s}^{2}$, variance of the random slopes in the linear mixed-effects model; $\sigma_{ɛ}^{2}$, variance of the residual errors in the linear mixed-effects model.

###### 

Sample size estimates for the AD and MCI groups using a linear mixed-effects model for KN-BSI^\*^

  Outcome measure                          Annual % change±SE        $\sigma_{s}^{2}$   $\sigma_{ɛ}^{2}$   N/arm not controlling for   N/arm controlling for
  ----------------------------------- ----------------------------- ------------------ ------------------ --------------------------- -----------------------
  *KN-BSI whole brain*                                                                                                                
  CN                                   −0.38±0.06 \[−0.49, −0.26\]                                                                    
  All AD subjects                      −1.00±0.07 \[−1.13, −0.87\]         0.44               0.08             150 \[117, 199\]          386 \[301, 511\]
  *ApoE* *ɛ*4 non-carriers with AD     −0.87±0.12 \[−1.11, −0.64\]         0.58               0.08             243 \[152, 447\]          750 \[470, 1381\]
  *ApoE* *ɛ*4 carriers with AD         −1.08±0.08 \[−1.24, −0.93\]         0.34               0.07              105 \[80, 142\]          246 \[188, 334\]
  All MCI subjects                     −0.82±0.05 \[−0.93, −0.72\]         0.45               0.09             231 \[182, 304\]          785 \[616, 1033\]
  *ApoE* *ɛ*4 non-carriers with MCI    −0.74±0.08 \[−0.89, −0.58\]         0.44               0.09             289 \[198, 460\]         1210 \[829, 1929\]
  *ApoE* *ɛ*4 carriers with MCI        −0.90±0.07 \[−1.05, −0.76\]         0.45               0.08             189 \[141, 269\]          558 \[414, 792\]
  *KN-BSI hippocampus*                                                                                                                
  CN                                   −0.58±0.14 \[−0.87, −0.30\]                                                                    
  All AD subjects                      −3.34±0.20 \[−3.74, −2.94\]         4.14               0.60              120 \[96, 154\]          176 \[141, 226\]
  *ApoE* *ɛ*4 non-carriers with AD     −2.68±0.32 \[−3.32, −2.03\]         4.54               0.50             194 \[127, 331\]          317 \[208, 541\]
  *ApoE* *ɛ*4 carriers with AD         −3.78±0.24 \[−4.26, −3.29\]         3.36               0.67              83 \[65, 109\]            116 \[91, 152\]
  All MCI subjects                     −2.76±0.16 \[−3.07, −2.46\]         4.27               0.49             173 \[140, 218\]          277 \[225, 351\]
  *ApoE* *ɛ*4 non-carriers with MCI    −2.02±0.22 \[−2.46, −1.59\]         4.01               0.44             299 \[204, 480\]          590 \[402, 947\]
  *ApoE* *ɛ*4 carriers with MCI        −3.44±0.20 \[−3.84, −3.03\]         3.61               0.54              100 \[80, 128\]          145 \[116, 185\]

^\*^The number of subjects per arm required to detect a 25% reduction in the mean rate of decline at the *p* \< 0.05 level with 80% power, assuming a 12-month trial with MRI scans every 6 months, is shown before and after controlling for normal aging. SE, standard error of the mean; CI, confidence interval; KN-BSI, k-means normalized boundary shift integral; CN, cognitively normal; AD, Alzheimer's disease; MCI, mild cognitive impairment; $\sigma_{s}^{2}$, variance of the random slopes in the linear mixed-effects model; $\sigma_{ɛ}^{2}$, variance of the residual errors in the linear mixed-effects model.

###### 

Comparison of 1-year atrophy rates in the whole brain and hippocampus between *ApoE* *ɛ*4 carriers and non-carriers^\*^

  Outcome measure         Annual % change±SE \[95% CI\]^\*^            *p* value           
  ---------------------- ----------------------------------- ----------------------------- ---------
  *KN-BSI whole brain*                                                                     
  AD                         −1.08±0.08 \[−1.24, −0.93\]      −0.87±0.12 \[−1.11, −0.64\]    0.13
  MCI                        −0.90±0.07 \[−1.05, −0.76\]      −0.74±0.08 \[−0.89, −0.58\]    0.13
  *KN-BSI hippocampus*                                                                     
  AD                         −3.78±0.24 \[−4.26, −3.29\]      −2.68±0.32 \[−3.32, −2.03\]   \<0.01
  MCI                        −3.44±0.20 \[−3.84, −3.03\]      −2.02±0.22 \[−2.46, −1.59\]   \<0.001

^\*^The mean atrophy rates were estimated from baseline, 6-month, and 12-month scans using the linear mixed-effects model. SE, standard error of the mean; KN-BSI, k-means normalized boundary shift integral; AD, Alzheimer's disease; MCI, mild cognitive impairment.

###### 

Sample size estimates for the AD and MCI groups using a linear mixed-effects model^\*^

  Outcome measure                  AD                   MCI                               
  ----------------------- -------------------- --------------------- -------------------- ----------------------
  KN-BSI hippocampus        120 \[96, 154\]      176 \[141, 226\]      173 \[140, 218\]      277 \[225, 351\]
  KN-BSI whole brain        150 \[117, 199\]     386 \[301, 511\]      231 \[182, 304\]     785 \[616, 1033\]
  FS entorhinal cortex      317 \[223, 484\]     348 \[245, 532\]      412 \[300, 599\]      467 \[341, 679\]
  FS hippocampus            270 \[196, 398\]     347 \[251, 510\]      341 \[255, 477\]      474 \[356, 663\]
  FS lateral ventricle      480 \[316, 819\]    1538 \[1010, 2622\]    203 \[162, 261\]      690 \[551, 891\]
  FSx entorhinal cortex    642 \[397, 1213\]     870 \[537, 1644\]    1025 \[636, 1923\]    1502 \[931, 2818\]
  FSx hippocampus          753 \[450, 1510\]    1169 \[699, 2342\]    870 \[558, 1541\]     1458 \[936, 2582\]
  FSx lateral ventricle     536 \[345, 947\]    1815 \[1166, 3204\]   1321 \[778, 2721\]   5907 \[3478, 12169\]
  CDR-SB                    398 \[272, 637\]     434 \[297, 694\]      575 \[399, 897\]     660 \[458, 1030\]
  ADAS-Cog                 766 \[454, 1556\]     431 \[255, 876\]     922 \[586, 1658\]      475 \[302, 854\]
  MMSE                     1263 \[660, 3330\]   1039 \[542, 2738\]    670 \[453, 1091\]      563 \[380, 916\]

^\*^The number of subjects per arm required to detect a 25% reduction in the mean rate of decline at the *p* \< 0.05 level with 80% power, assuming a 12-month trial with MRI scans every 6 months, is shown with and without controlling for normal aging. AD, Alzheimer's disease; MCI, mild cognitive impairment; KN-BSI, k-means normalized boundary shift integral; FS, FreeSurfer v5.3 longitudinal stream; FSx, FreeSurfer v5.3 cross-sectional; CDR-SB, Clinical Dementia Rating Scale Sum of Boxes; ADAS-Cog, Alzheimer's Disease Assessment Scale-Cognitive Subscale; MMSE, Mini-Mental State Examination.

###### 

Sample size comparison using bootstrap sampling^\*^

  Outcome measure                           AD                        MCI                                       
  ----------------------------- -------------------------- -------------------------- ------------------------- -------------------------
  *KN-BSI hippocampus*                                                                                          
  versus KN-BSI whole brain           −30 \[−62, 1\]         −210 \[−405, −97\]^†^      −58 \[−102, −16\]^†^     −507 \[−1053, −248\]^†^
  versus FS entorhinal cortex     −196 \[−305, −108\]^†^     −172 \[−331, −56\]^†^     −239 \[−359, −139\]^†^     −190 \[−419, −29\]^†^
  versus FS hippocampus            −150 \[−250, −1\]^†^        −170 \[−358, 37\]        −168 \[−263, −79\]^†^     −197 \[−465, −32\]^†^
  versus FS lateral ventricle      −360 \[−805, −1\]^†^     −1362 \[−4524, −133\]^†^       −30 \[−91, 35\]       −413 \[−948, −138\]^†^
  versus CDR-SB                   −278 \[−383, −181\]^†^     −257 \[−391, −133\]^†^    −402 \[−563, −256\]^†^    −382 \[−624, −182\]^†^
  versus ADAS-Cog                −645 \[−1150, −358\]^†^     −254 \[−505, −88\]^†^     −749 \[−1163, −491\]^†^    −197 \[−426, −33\]^†^
  versus MMSE                    −1143 \[−2128, −681\]^†^   −863 \[−1746, −469\]^†^    −497 \[−758, −315\]^†^     −285 \[−570, −96\]^†^
  *KN-BSI whole brain*                                                                                          
  versus FS entorhinal cortex     −167 \[−279, −76\]^†^         38 \[−157, 272\]        −180 \[−304, −77\]^†^       318 \[−17, 899\]
  versus FS hippocampus             −120 \[−223, 38\]           39 \[−173, 358\]        −109 \[−218, −5\]^†^        311 \[−41, 861\]
  versus FS lateral ventricle       −331 \[−773, 31\]         −1152 \[−4228, 97\]          28 \[−32, 95\]           94 \[−310, 538\]
  versus CDR-SB                   −248 \[−352, −153\]^†^       −48 \[−219, 196\]       −344 \[−506, −195\]^†^       125 \[−229, 718\]
  versus ADAS-Cog                −616 \[−1120, −326\]^†^       −45 \[−332, 236\]       −691 \[−1110, −434\]^†^      310 \[−46, 897\]
  versus MMSE                    −1114 \[−2074, −650\]^†^   −653 \[−1492, −223\]^†^    −439 \[−708, −257\]^†^       222 \[−167, 816\]

^\*^The sample sizes were estimated assuming a 12-month trial with assessments every 6 months. ^†^Statistically significant based on the bootstrap sampling procedure. AD, Alzheimer's disease; MCI, mild cognitive impairment; KN-BSI, k-means normalized boundary shift integral; FS, FreeSurfer v5.3 longitudinal stream; CDR-SB, Clinical Dementia Rating Scale Sum of Boxes; ADAS-Cog, Alzheimer's Disease Assessment Scale-Cognitive Subscale; MMSE, Mini-Mental State Examination.

[^1]: Data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (<http://adni.loni.usc.edu>). As such, the investigators within the ADNI contributed to the design and implementation of the ADNI and/or provided data but did not participate in the analysis or writing of this report. A complete listing of ADNI investigators can be found at: <http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf>
